Trial Profile

A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary)
Indications Thyroid cancer
Focus Therapeutic Use

Most Recent Events

04 Jun 2024 Results(n=17) of an investigator-initiated phase II clinical trial evaluating regorafenib in this population,presented at the 60th Annual Meeting of the American Society of Clinical Oncology
29 May 2024 Primary endpoint has not been met. (10-month Progression-free Survival (PFS) Rate [MTC Cohort]), according to an abstract presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com